The objective of this study as to characterize the PK and drug-drug interactions of MOX after a single oral dose (8 mg fixed in W. bancrofti-infected subjects) in combination with ALB with or without DEC as a part of a clinical trial for the treatment of LF. The gene discussed is ALB; the disease is Lassa fever.